In May, the inaugural Interventional Glaucoma Consortium (IGC) Global was held in Dublin. This program convened more than 30 glaucoma specialists from around the world to discuss pressing topics and questions in interventional glaucoma care. Curated by Program Chairs Iqbal Ike K. Ahmed, MD, FRCSC; Henny Beckers, MD, PhD, FEBOphth; and Arsham Sheybani, MD, the agenda was filled with talks and panels dedicated to topics such as selective laser trabeculoplasty as first-line therapy, standalone MIGS, sustained drug delivery, emerging technologies, and more.
Most notable, however, were the thought-provoking conversations that took place among the IGC Global faculty members amid the more organized presentations. Lively discussions emphasized not only the contrasting perspectives in glaucoma care but also the true complexity of the disease. If glaucoma were clear-cut, its management would be standard, and providers would never cease to align. As we know, this is far from the case.
This issue of GT focuses on one of the more complex aspects of this complex disease: normal-tension glaucoma (NTG). Contributors share insights into the diagnosis and management of this subtype as well as on IOP variability and masqueraders of NTG. Although evident that much remains uncertain, many parties—physicians, researchers, and companies—are working to enhance the understanding and care of NTG. We hope you enjoy reading, and, as always, if a point (or counterpoint) comes to mind, we invite you to reach out.
